Chronic Kidney Disease | Unmet Need | US/EU | 2021
Because of the lack of disease-modifying agents for CKD, treatment is aimed at minimizing the symptoms and complications arising from progressively diminished kidney function and treating the cause of impaired kidney function. This content specifically explores therapies that aim to halt the progressive decline in kidney function and lower the risk of adverse outcomes such as ESRD, cardiovascular, or renal death. A growing body of evidence shows that SGLT-2 inhibitors benefit CKD patients. This report examines the performance of key SGLT-2 inhibitor brands and remaining unmet need in a difficult-to-treat and highly prevalent disease.
QUESTIONS ANSWERED
- How do nephrologists rate SGLT-2 inhibitors, diuretics, and RAAS inhibitors on selected renal endpoints?
- Which attribute has the greatest unmet need: preservation of eGFR or reduction in the risk of progression to ESRD?
- How do drug attributes such as risk of MACE and drug price influence prescribing preference?
- Do U.S. and European nephrologists have different perceptions of unmet need in the treatment of CKD?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European nephrologists for a hypothetical new CKD drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European nephrologists fielded in March 2021
Key companies: AstraZeneca, Johnson and Johnson, Eli Lilly
Key drugs: Invokana, Jardiance, Farxiga
